Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Seoul, Korea.
Korean J Anesthesiol. 2011 Feb;60(2):83-9. doi: 10.4097/kjae.2011.60.2.83. Epub 2011 Feb 25.
Propofol is used as an induction and maintenance agent for general anesthesia but it can cause adverse reactions like hyperlipidemia, growth of microorganisms, and pulmonary embolisms. Microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol. We aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain of microemulsion propofol.
The candidates included eighty patients, 19-60 years old and ASA I-II. They were randomly classified into four groups and pretreated with normal saline, sufentanil 0.1 µg/kg, 0.2 µg/kg or 0.3 µg/kg before injection of microemulsion propofol. Five minutes after receiving pretreatment drug, 2 mg/kg of microemulsion propofol was injected and VAS was recorded.
There were no significant differences in the incidence of injection pain among the groups. Severity of injection pain was significantly lower in the sufentanil 0.3 µg/kg group than normal saline and sufentanil 0.1 µg/kg group. Significant differences in blood pressure and heart rate were observed in sufentanil groups only after endotracheal intubation. One patient each in sufentanil 0.1 µg/kg and 0.3 µg/kg group experienced mild cough, one from sufentanil 0.3 µg/kg group experienced dizziness and another showed signs of hypoxia. One patient each in normal saline and sufentanil 0.1 µg/kg group showed clinical symptoms of phlebitis in the injection area.
Pretreatment with sufentanil 0.3 µg/kg reduced the severity of microemulsion propofol injection pain without increasing arterial blood pressure and heart rate after endotracheal intubation.
丙泊酚被用作全身麻醉的诱导和维持药物，但它会引起不良反应，如高血脂、微生物生长和肺栓塞。微乳丙泊酚的开发是为了避免这些副作用，但注射时疼痛的发生率和严重程度高于脂乳丙泊酚。我们旨在比较舒芬太尼在镇痛剂量下对减轻微乳丙泊酚注射疼痛的影响。
入选患者 80 例，年龄 19-60 岁，ASA I-II 级。他们随机分为四组，在注射微乳丙泊酚前分别给予生理盐水、舒芬太尼 0.1μg/kg、0.2μg/kg 或 0.3μg/kg 预处理。接受预处理药物 5 分钟后，给予 2mg/kg 的微乳丙泊酚，记录 VAS。
各组注射疼痛的发生率无显著差异。与生理盐水和舒芬太尼 0.1μg/kg 组相比，舒芬太尼 0.3μg/kg 组的注射疼痛严重程度显著降低。只有在气管插管后，舒芬太尼组的血压和心率才出现显著差异。舒芬太尼 0.1μg/kg 和 0.3μg/kg 组各有 1 例患者出现轻度咳嗽，舒芬太尼 0.3μg/kg 组有 1 例患者出现头晕，另 1 例患者出现缺氧迹象。生理盐水和舒芬太尼 0.1μg/kg 组各有 1 例患者在注射部位出现静脉炎的临床症状。
舒芬太尼 0.3μg/kg 预处理可减轻微乳丙泊酚注射疼痛的严重程度，而不会增加气管插管后动脉血压和心率。
